Steven J Yakubov, Mscai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2851154/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. New England Journal of Medicine, 2019, 380, 1706-1715.	13.9	2,530
2	Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. New England Journal of Medicine, 2014, 370, 1790-1798.	13.9	2,411
3	Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. New England Journal of Medicine, 2017, 376, 1321-1331.	13.9	2,249
4	Transcatheter Aortic Valve Replacement UsingÂaÂSelf-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at ExtremeÂRisk for Surgery. Journal of the American College of Cardiology, 2014, 63, 1972-1981.	1.2	902
5	Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 62, 108-118.	1.2	382
6	2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 113-121.	1.2	371
7	3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 67, 2565-2574.	1.2	296
8	Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation. Journal of the American College of Cardiology, 2014, 64, 565-572.	1.2	200
9	Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. JACC: Cardiovascular Interventions, 2018, 11, 160-168.	1.1	147
10	Predicting Early and Late Mortality After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 343-352.	1.2	146
11	Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 1868-1877.	1.2	128
12	Bioprosthetic Aortic Valve Leaflet Thickening in the Evolut Low RiskÂSub-Study. Journal of the American College of Cardiology, 2020, 75, 2430-2442.	1.2	127
13	One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial. JAMA Cardiology, 2018, 3, 968.	3.0	121
14	1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses. JACC: Cardiovascular Interventions, 2017, 10, 1034-1044.	1.1	100
15	Neurological Events Following Transcatheter Aortic Valve Replacement and Their Predictors. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	79
16	Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2869-2876.e7.	0.4	62
17	Outcomes in the Randomized CoreValve US Pivotal High Risk Trial in Patients With a Society of Thoracic Surgeons Risk Score of 7% or Less. JAMA Cardiology, 2016, 1, 945.	3.0	62
18	Comparison of a Complete Percutaneous Versus Surgical Approach to Aortic Valve Replacement and Revascularization in Patients at Intermediate Surgical Risk. Circulation, 2019, 140, 1296-1305.	1.6	59

#	Article	IF	CITATIONS
19	2-Year Outcomes After Iliofemoral Self-Expanding Transcatheter Aortic ValveÂReplacement in Patients With SevereÂAortic Stenosis Deemed ExtremeÂRisk for Surgery. Journal of the American College of Cardiology, 2015, 66, 1327-1334.	1.2	55
20	Impact of Annular Size on Outcomes After Surgical or Transcatheter Aortic Valve Replacement. Annals of Thoracic Surgery, 2018, 105, 1129-1136.	0.7	36
21	Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). American Journal of Cardiology, 2016, 118, 396-402.	0.7	30
22	Transcatheter Aortic Valve Replacement Versus Surgery in Women at High Risk for Surgical Aortic Valve Replacement (from the CoreValve US High Risk Pivotal Trial). American Journal of Cardiology, 2016, 118, 560-566.	0.7	29
23	Clinical impact of baseline chronic kidney disease in patients undergoing transcatheter or surgical aortic valve replacement. Catheterization and Cardiovascular Interventions, 2019, 93, 740-748.	0.7	27
24	Durability and Clinical Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses. Circulation: Cardiovascular Interventions, 2019, 12, e008155.	1.4	26
25	Safety and Efficacy of Self-Expanding TAVR inÂPatients With AortoventricularÂAngulation. JACC: Cardiovascular Imaging, 2016, 9, 973-981.	2.3	25
26	Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. Current Medical Research and Opinion, 2009, 25, 2631-2641.	0.9	22
27	Predictors and Risk Calculator of Early Unplanned Hospital Readmission Following Contemporary Self-Expanding Transcatheter Aortic Valve Replacement from the STS/ACC TVT Registry. Cardiovascular Revascularization Medicine, 2020, 21, 263-270.	0.3	22
28	Causes of death from the randomized CoreValve US Pivotal High-Risk Trial. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 1293-1301.e1.	0.4	20
29	4-Dimensional Intracardiac Echocardiography in Transcatheter Tricuspid Valve Repair With the MitraClipÂSystem. JACC: Cardiovascular Imaging, 2020, 13, 1591-1600.	2.3	20
30	Complications After Self-expanding Transcatheter or Surgical Aortic Valve Replacement. Seminars in Thoracic and Cardiovascular Surgery, 2017, 29, 321-330.	0.4	17
31	Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Low-Gradient Aortic Stenosis. JACC: Cardiovascular Imaging, 2019, 12, 67-80.	2.3	16
32	Direct Aortic Access for Transcatheter Aortic Valve Replacement Using a Self-Expanding Device. Annals of Thoracic Surgery, 2018, 105, 484-490.	0.7	15
33	Incidence and Outcomes of Infective Endocarditis After Transcatheter or Surgical Aortic Valve Replacement. Journal of the American Heart Association, 2021, 10, e020368.	1.6	14
34	Conventional versus modified delivery system technique in commissural alignment from the Evolut <scp>lowâ€risk CT substudy</scp> . Catheterization and Cardiovascular Interventions, 2022, 99, 924-931.	0.7	14
35	Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery. JAMA Cardiology, 2019, 4, 810.	3.0	12
36	One-Year Outcomes of Transcatheter AorticÂValve Replacement in Patients WithÂEnd-Stage Renal Disease. Annals of Thoracic Surgery, 2017, 103, 1392-1398.	0.7	10

#	Article	IF	CITATIONS
37	Transcatheter aortic valve replacement in patients with severe mitral or tricuspid regurgitation at extreme risk for surgery. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1991-1999.	0.4	9
38	The initial U.S. experience with the Tempo active fixation temporary pacing lead in structural heart interventions. Catheterization and Cardiovascular Interventions, 2020, 95, 1051-1056.	0.7	9
39	Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010258.	1.4	9
40	4-Dimensional Intracardiac Echocardiography in Transcatheter Mitral Valve Repair With the Mitraclip System. JACC: Cardiovascular Imaging, 2021, 14, 2033-2040.	2.3	9
41	Functional Status After Transcatheter and Surgical Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2022, 15, 728-738.	1.1	8
42	Overcoming the transcatheter aortic valve replacement Achilles heel: coronary re-access. Annals of Cardiothoracic Surgery, 2020, 9, 468-477.	0.6	6
43	1-Year Outcomes following Bioprosthetic Valve Fracture to Facilitate Valve-in-Valve Transcatheter Aortic Valve Replacement. Structural Heart, 2021, 5, 312-318.	0.2	6
44	Innovations in Transcatheter Valve Technology. Interventional Cardiology Clinics, 2018, 7, 489-501.	0.2	5
45	Percutaneous approaches for retrieval of an embolized or malpositioned left atrial appendage closure device: A multicenter experience. Heart Rhythm, 2020, 17, 1545-1553.	0.3	5
46	Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study. Circulation: Cardiovascular Interventions, 2021, 14, e010609.	1.4	4
47	Outcomes in Patients With Asymptomatic Aortic Stenosis (from the Evolut Low Risk Trial). American Journal of Cardiology, 2022, 168, 110-116.	0.7	4
48	The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale. American Heart Journal, 2019, 216, 82-90.	1.2	3
49	Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical Study. Cardiovascular Revascularization Medicine, 2021, 26, 12-16.	0.3	3
50	Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank. Catheterization and Cardiovascular Interventions, 2021, 98, 904-913.	0.7	3
51	First Reported 4D Volume Intracardiac Echocardiography Guided Left Atrial Appendage Closure in the USA. Structural Heart, 2020, 4, 72-74.	0.2	1
52	Left Atrial Appendage Closure. Cardiac Electrophysiology Clinics, 2020, 12, 47-54.	0.7	1
53	Mechanisms of death in low risk patients after transcatheter or surgical aortic valve replacement. Cardiovascular Revascularization Medicine, 2022, , .	0.3	1
54	Acute Coronary Syndrome in Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 2534-2536.	1.1	0

#	Article	IF	CITATIONS
55	TAVR and DAPT: Are We Any Closer to the Answer?. Structural Heart, 2018, 2, 419-420.	0.2	0
56	#PCI2021: The Trend Is Our Friend. Cardiovascular Revascularization Medicine, 2021, 31, 17-18.	0.3	0